
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is supported by a resilient WAKIX franchise, with 3Q26 revenue of $268.9 million, about 400 net patient additions, and roughly 8,950 to 9,350 patients on therapy, while management reaffirmed 2026 net revenue guidance of $1.00 billion–$1.04 billion. The positive outlook is also driven by a well-funded balance sheet of about $1.05 billion in cash and investments, giving it flexibility to advance BP-205 and other CNS assets while pursuing larger business-development opportunities. Despite litigation and orexin competition, BP-205’s 94-patient MAD data, with no serious or severe adverse events and a roughly 29-hour half-life, plus pitolisant lifecycle catalysts such as GR and HD, strengthen the long-term growth case.
Bears say
Harmony Biosciences Hldgs is facing a negative fundamental setup because WAKIX remains exposed to intensifying competition in the sodium oxybate market, while earlier-than-expected generic pitolisant competition could directly pressure the company’s core revenue base. Growth in new patient adds for WAKIX may also slow more than expected, limiting momentum in its only commercial engine and leaving results highly dependent on one product. In addition, the pipeline carries meaningful binary risk, as clinical trials for PWS, DM1, DS/LGS, and Fragile X syndrome may fail to deliver, reducing the chance of near-term diversification.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Harmony Biosciences Holdings (HRMY) Forecast
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares